• Title/Summary/Keyword: Biologic

Search Result 499, Processing Time 0.029 seconds

Psoriasis flares after COVID-19 vaccination: adherence to biologic therapy reduces psoriasis exacerbations: a case-control study

  • Martina Burlando;Astrid Herzum;Emanuele Cozzani;Aurora Parodi
    • Clinical and Experimental Vaccine Research
    • /
    • v.12 no.1
    • /
    • pp.80-81
    • /
    • 2023
  • This study aimed to evaluate if patients under biologics have a lower risk of psoriasis flares after coronavirus disease 2019 (COVID-19) vaccination than other psoriatic patients. Of 322 recently vaccinated patients admitted for psoriasis at the Dermatological Psoriasis Unit during January and February 2022, 316 (98%) had no psoriasis flares after COVID-19 vaccination (79% under biologic treatment, 21% not biologically treated) and 6 (2%) presented psoriasis flares after COVID-19 vaccination (33.3% under biologic treatment, 66.6% not biologically treated). Overall, psoriasis patients under biologic treatment, developed fewer psoriasis flares after COVID-19 vaccination (33.3%), than patients not under biologic treatment (66.6%) (p=0.0207; Fisher's exact test).

Clinical Cases on the Restorative Procedure Preserving the Biologic Width (생물학적 폭경을 고려한 보철임상 증례)

  • Kim, Jeong-Ho
    • Journal of the Korean Academy of Esthetic Dentistry
    • /
    • v.8 no.1
    • /
    • pp.28-35
    • /
    • 1999
  • The preservation of a healthy periodontal attachment is the most significant factor in the long-term prognosis of a restored tooth. The 'Biologic Width' is composed of the connective tissue attachment and the epithelial attachment in the dentogingival junction. The violation of the biologic width may result in a progressive inflammatory process and crestal bone loss. So a careful soft tissue management is needed to preserve it for the gingival health and an esthetic restoration. The following clinical cases show the five different situations of the violation of the biologic width and their management.

  • PDF

Consideration of Vertical Position for predictable posterior implant - Deep implantation for Implant Biologic width (예지성 있는 구치부 임플란트를 위한 임플란트의 수직적 깊이에 대한 고려 Implant Biologic width를 위한 Deep Implantation)

  • Yun, Woo-Hyuk
    • Journal of the Korean Academy of Esthetic Dentistry
    • /
    • v.28 no.1
    • /
    • pp.27-41
    • /
    • 2019
  • For predictable posterior implants, appropriate soft tissue thickness, called the biologic width, is required around the implant for crestal bone stability. In order to do so, it seems that there are many cases where the implant should be positioned deeper than the depth that we previously thought was appropriate or inevitable limit. I would like to share my clinical experience about the vertical position of the posterior implant with the case reports and the related surgical technique.

Electrochemical Determination of Artemisinin Using a Multi-wall Carbon Nanotube Film-modified Electrode

  • Yang, Xiaofeng;Gan, Tian;Zheng, Xiaojiang;Zhu, Dazhai;Wu, Kangbing
    • Bulletin of the Korean Chemical Society
    • /
    • v.29 no.7
    • /
    • pp.1386-1390
    • /
    • 2008
  • Artemisinin, the effective ingredient of Chinese herb Artemisia annua L (Qinghao in Chinese), has been proved to be effective to antimalarial. Herein, a reliable, sensitive and convenient electrochemical method was developed for the determination of artemisinin utilizing the excellent properties of multi-wall carbon nanotube (MWNT). The electrochemical behavior of artemisinin was investigated. It is found that the reduction peak current of artemisinin remarkably increases and the peak potential shifts positively by 240 mV at the MWNT film-modified electrode. These phenomena indicate that the MWNT film exhibits efficient catalytic activity to the electrochemical reduction of artemisinin. The effects of pH value, amount of MWNT, scan rate and accumulation time were examined. The limit of detection (S/N = 3) is as low as 10 $\mu$ g $L^{-1}$. Finally, this newly developed method was used to determine the content of artemisinin in Artemisia annua L.

A humeral hemiarthroplasty with biologic resurfacing of the glenoid using an allo-Achilles tendon: two case reports

  • Choi, Ki-Yong;Jung, Kyu-Hak;Kim, Young-Kyu;Yoon, Young-Hyun
    • Clinics in Shoulder and Elbow
    • /
    • v.24 no.1
    • /
    • pp.27-31
    • /
    • 2021
  • A hemiarthroplasty with biologic resurfacing of the glenoid is one procedure that can be performed in young patients where total shoulder arthroplasty may be difficult. The authors introduced two cases in which this procedure was performed. This approach is one treatment option for young glenoid humeral arthritis patients that addresses some of the shortcomings of an isolated hemiarthroplasty.

Synthesis and Characterization of Lactobionic Acid Grafted Phenylalanyl-Glycyl-Chitosan

  • Li, He-Ping;Li, Shan;Wang, Zhou-Dong;Qin, Long
    • Journal of the Korean Chemical Society
    • /
    • v.55 no.6
    • /
    • pp.978-982
    • /
    • 2011
  • In order to enhance the target action of chitosan-based drug, this paper firstly prepared phenylalanyl-glycylchitosan (Phe-Gly-CS) by grafting the key intermediate, bromoacetyl-phenylalanine (BA-Phe) onto chitosan. Then the target sugar molecule, lactobionic acid (LA), was grafted to Phe-Gly-CS and the topic compound lactobionic acid grafted phenylalanyl-glycyl-chitosan (Phe-Gly-CS-LA) was finally obtained in a yield of 78.8%. The product were characterized by FTIR, MS and 1H NMR. The preparing condition of BA-Phe was optimized as follows: the best pH was 10-11, the optimum temperature was $-4^{\circ}C$, the reaction time was 1.5 h.

Management of severe hidradenitis suppurativa with biologic therapy and wide excision

  • Lim, Shi Yu Derek;Cheong, Ee Cherk;Oon, Hazel H.
    • Archives of Plastic Surgery
    • /
    • v.46 no.3
    • /
    • pp.272-276
    • /
    • 2019
  • Hidradenitis suppurativa (HS) is a chronic inflammatory follicular occlusive disease that involves the intertriginous areas. Treatment methods include conventional topical and systemic medication, radiotherapy, biologic agents, and surgical excision. Of late, there has been an increased focus on the use of biologic agents in patients with moderate to severe HS. Here, we present the case of a 46-year-old man with Hurley stage III HS for whom wide excision was ultimately curative, after aggressive medical therapy with the use of infliximab and adalimumab had succeeded in limiting the body surface area affected by the disease. This case demonstrates the effective treatment of severe HS with a combination of biologic therapy and surgery.

Cost-Minimization Analysis of Biologic Disease-Modifying Antirheumatic Drugs Administered by Subcutaneous Injections in Patients with Rheumatoid Arthritis (피하주사로 투여하는 생물학적 항류마티스 제제의 비용 최소화 연구)

  • Park, Seung-Hoo;Lee, Min-Young;Lee, Eui-Kyung
    • Korean Journal of Clinical Pharmacy
    • /
    • v.26 no.1
    • /
    • pp.59-69
    • /
    • 2016
  • Background: The subcutaneous formulation of biologic disease-modifying antirheumatic drugs (DMARDs) was preferred due to favored self-administration and would be an economical treatment option for patients with rheumatoid arthritis. This study was to compare the economic impact of biologic DMARDs administered by subcutaneous injection in patients with rheumatoid arthritis who had inadequate response to conventional DMARDs. Methods: The cost-minimization analysis was conducted to estimate the lifetime health care costs of treatment sequences with subcutaneous biologic DMARDs as first-line therapy from a health care system perspective. The Markov model was developed to represent the transitions through treatment sequences based on American College of Rheumatology response rate and discontinuation rate. The health care costs comprised the cost of medications, administration, dispensing, outpatient visits, test/diagnostic examination, palliative therapy and treatment of serious infection. All costs were expressed in 2016 Korean Won (KRW) and discounted at 5%. Results: The mean lifetime health care cost per patient was lowest in the etanercept sequence, which was estimated at KRW 63,441,679. The incremental costs of the treatment sequence started with adalimumab, golimumab, abatacept, and tocilizumab were KRW 7,985,730, KRW 4,064,669, KRW 2,869,947, and KRW 4,282,833, respectively, relative to etanercept sequence. These differences in costs mainly were attributable to medication costs. One-way and probabilistic sensitivity analyses confirmed that etanercept represented the option with the lowest cost compared with comparators. Conclusion: This study found that etanercept is likely a cost-saving treatment option among subcutaneous biologic DMARDs in patients with rheumatoid arthritis.

Preparation and In Vitro Release of Ramose Chitosan-Based-5-Fluorouracil Microspheres

  • Li, He-Ping;Li, Hui;Wang, Zhou-Dong;Zhang, Juan-Juan;Deng, Man-Feng;Chen, San-Long
    • Journal of the Korean Chemical Society
    • /
    • v.57 no.1
    • /
    • pp.88-93
    • /
    • 2013
  • In order to construct a controlled release system of drugs and to reduce toxic side effects of 5-fluorouracil, the novel ramose chitosan-based-5-fluorouracil microspheres (CS-FU-MS) were prepared. Firstly, using chitosan (CS) as carriers and 5-fluorouracil (5-FU) as a model drug, ramose chitosan-based-5-fluorouracil (CS-FU) was efciently synthesized by chemical crosslinking method through microwave irradiation, drug loading was 10.6%; Secondly, CS-FU-MS were prepared by CS-FU self-assembled under the dialysis conditions and the free 5-FU was encapsulated further at the same time. The size dispersivity of particles is uniform, and the average diameter of the CS-FU-MS was $4{\mu}m$. The drug encapsulation efficiency was 76.1%, and the drug loading was increased to 26.22%. CS-FU-MS maintain the zero-order release time in PBS (pH = 7.4) and HCl/KCl (pH = 1.2) dialysis medium was 40h and 34h respectively, and the cumulative release were 58.89% and 79.33% in 182 h. The results showed that CS-FU-MS have excellent sustained release properties.

A Feasibility Study of the IMRT Optimization with Pseudo-Biologic Objective Function (유사생물학적 대상 함수를 이용한 IMRT 최적화 알고리즘 가능성에 관한 연구)

  • Yi, Byong-Yong;Cho, Sam-Ju;Ahn, Seung-Do;Kim, Jong-Hoon;Choi, Eun-Kyung;Chang, Hye-Sook;Kwon, Soo-Il
    • Journal of Radiation Protection and Research
    • /
    • v.26 no.4
    • /
    • pp.417-424
    • /
    • 2001
  • The pseudo-biologic objective function has been designed for the IMRT optimization. The RTP Tool Box (RTB) was used for this study. The pseudo-biologic function is similar to the biological objective function in mathematical shape, but uses physical parameters. The concepts of the TCI (Target Coverage Index) and the OSI (Organ Score Index) have been introduced for the target and the normal organs, respectively. The pseudo-biologic objective function s has been defined using these TCI and OSI's. The OSI's from the pseudo-biological function showed better results than from the physical functions, while TCI's showed similar tendency. These results revealed the feasibility of the pseudo-biologic function as an IMRT objective function.

  • PDF